Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prosonix, a UK-based speciality pharmaceutical firm developing a portfolio of inhaled Respiratory Medicines by Design, has entered into a global licensing agreement with Mylan, for its inhaled respiratory products, PSX1001 and PSX1050, which emerged from Prosonix's particle engineering platform.
Subscribe to our email newsletter
PSX1001 and PSX1050 are being developed as generic versions to GlaxoSmithKline’s pressurised metered dose inhalers (pMDI) Flixotide and Flovent, respectively.
Flixotide and Flovent contain the active ingredient fluticasone propionate, a potent inhaled corticosteroid, and are used to treat asthma.
As part of the deal, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories.
Mylan has marketing rights for PSX1001 and PSX1050 in the US, Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States.
Prosonix CEO and co-founder David Hipkiss said the agreement with Mylan for the global development and commercialisation of PSX1001 and PSX1050 is a major milestone that reflects the outstanding contribution of the whole Prosonix team.
"As a world leader in manufacturing and commercialising high-value, difficult-to-manufacture generics and with a growing respiratory franchise, we believe Mylan is the ideal partner to ensure PSX1001 and PSX1050 are a commercial success and a strong validation of our ‘Respiratory Medicine by Design’ philosophy," Hipkiss said.
Mylan president Rajiv Malik said the company is happy to enter into this agreement with Prosonix as it represents another development milestone in its global respiratory franchise, one of its key strategic growth drivers, and strengthens its portfolio of difficult to develop and manufacture products.
"Further, Prosonix’s expertise in the development of inhaled respiratory products perfectly complements the strength of Mylan’s respiratory R&D capabilities," Malik said.
"We look forward to a successful collaboration with Prosonix in the coming years as we bring to market generic versions of Flixotide and Flovent around the world."